ArticleCell death discovery2025
METTL3-mediated m6A modification of circCDKAL1 regulates macrophage M1 polarization and nasal epithelial cell barrier function in allergic rhinitis through IGF2BP2/JARID2/HMGB1 axis.
Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrated m6A methylome and transcriptome profiling of mRNAs and lncRNAs in nasal mucosal epithelial cells of allergic rhinitis patients undergoing allergen-specific immunotherapy.Clinical epigenetics · 2026Article
- The role of calcium homeostasis dysregulation in allergic rhinitis.Frontiers in immunology · 2026Review
- Regulation of macrophage polarization in chronic airway inflammatory diseases: immune interactions, metabolic reprogramming, and beyond.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic rhinitis (AR) is a chronic inflammatory disease that significantly impairs patients' quality of life, with CircCDKAL1 showing abnormal upregulation in AR patients, though its functional mechanisms remain unclear. In this study, we confirmed the identity of circCDKAL1 and its subcellular localization. Our findings revealed that circCDKAL1 expression was enhanced in samples of AR patients, AR mice and OVA-induced HNEpCs. Besides, circCDKAL1 silencing resulted in improvement of nasal mucosal epithelial barrier function/epithelial cell adhesion and promotion of macrophage M2 polarization in AR. Mechanistically, we discovered that circCDKAL1 was modified by m6A, which was mediated by METTL3. YTHDC1 promoted cytoplasmic output of m6A-modified circCDKAL1. In addition, circCDKAL1 destabilized JARID2 mRNA through interacting with IGF2BP2. Moreover, circCDKAL1 or HMGB1 silencing attenuated JARID2 silencing-mediated damages of epithelial cell adhesion and promotion of macrophage M1 polarization in OVA-induced HNEpCs. In conclusion, METTL3-mediated m6A modification of circCDKAL1, which was transferred from the nucleus to the cytoplasm by YTHDC1, promoted macrophage M1 polarization and impaired nasal mucosal epithelial barrier function/epithelial cell adhesion in AR through interacting with IGF2BP2 and regulating JARID2/HMGB1 axis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.